09.29.15
PRA Health Sciences and Alliance for Multispecialty Research (AMR) have partnered to develop a new approach to vaccine studies that will allow them to run more efficiently and effectively.
PRA's vaccine experience includes Phase I-IV adult and pediatric studies and has provided clinical development support for ten approved vaccines over the past five years, and supports four of the five top vaccine manufacturers.
AMR has vaccine trial experience for a variety of indications, including several bioterrorism-related government sponsored programs. Combining AMR and PRA expertise will allow for support of small to mid-size vaccine trials and subject retention to help sponsors meet enrollment timelines.
"This is an ideal collaboration," said Frank Hijek, PRA senior vice president, Strategic Drug Development. "It combines the expertise of PRA, one of the world's leading contract research organizations, and AMR one of the most effective clinical research site networks in the industry. Together, we can help sponsors get vaccines to the people who need them."
"Our partnership with PRA allows us to provide a simple approach to effective vaccine studies," said AMR chief executive officer Brenda Atchison. "Our respective expertise will allow us to make significant strides in implementing efficient solutions to smarter vaccine development."
The adult vaccine market continues to grow and is expected to nearly double by 2020 in the areas of infectious diseases, as well as cancer treatment and prevention.
PRA's vaccine experience includes Phase I-IV adult and pediatric studies and has provided clinical development support for ten approved vaccines over the past five years, and supports four of the five top vaccine manufacturers.
AMR has vaccine trial experience for a variety of indications, including several bioterrorism-related government sponsored programs. Combining AMR and PRA expertise will allow for support of small to mid-size vaccine trials and subject retention to help sponsors meet enrollment timelines.
"This is an ideal collaboration," said Frank Hijek, PRA senior vice president, Strategic Drug Development. "It combines the expertise of PRA, one of the world's leading contract research organizations, and AMR one of the most effective clinical research site networks in the industry. Together, we can help sponsors get vaccines to the people who need them."
"Our partnership with PRA allows us to provide a simple approach to effective vaccine studies," said AMR chief executive officer Brenda Atchison. "Our respective expertise will allow us to make significant strides in implementing efficient solutions to smarter vaccine development."
The adult vaccine market continues to grow and is expected to nearly double by 2020 in the areas of infectious diseases, as well as cancer treatment and prevention.